Amylyx reports Q4 EPS (55c) vs. 7c last year

“We made significant progress in 2024 across our pipeline, setting the stage for important milestones in the year ahead in orphan markets with high unmet need. We advanced our lead investigational asset avexitide into a pivotal Phase 3 trial and expect topline results in the first half of 2026. This year, we anticipate Week 48 data from our AMX0035 program in Wolfram syndrome, interim analysis data from our AMX0035 program in PSP, and early cohort data from our AMX0114 program in ALS,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx (AMLX). “With a strong balance sheet, strengthened by our recent financing that extended our expected cash runway through the end of 2026, we believe we are well positioned to achieve our goals.”